Pfizer is buying weight-loss drugmaker Metsera. Why Novo Nordisk is the real winner.
Shareholders Breathe Easier After Cautious Deal Outcome Investors in the Danish drugmaker appear relieved that a recent deal did not push the company into paying a premium for largely unproven treatments. Market sentiment suggests shareholders prefer measured spending over aggressive acquisitions that carry high scientific and commercial uncertainty. Why investors are relieved Lower risk of … Read more